Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer

Dabbous, Hisham Khalil; Mohamed, Yosry Abd El-Rahman; El-Folly, Runia Fouad; El-Talkawy, Mohamed Darwish; Seddik, Hani E; Johar, Dina; Sarhan, Mohammed A.

doi:10.1007/s12029-018-0088-1

Cited by 18 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in another study with 328 patients and the tumor M2-PK cut-off level of 4 U/mL, the sensitivity, specificity, PPV, and NPV were 71.4, 71.0, 73.5, and 94.4%, respectively [20]. In a study by Hisham K. Dabbous et al, M2-PK was the most sensitive and specific test in differentiating CRC from control subjects in fecal samples with sensitivity and specificity of 75, and 100%, respectively [14].…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

et al. 2020

View full text Add to dashboard Cite

Background: Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cancerous proliferating cells, has been used as a diagnostic biomarker for colorectal cancer (CRC). The aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population. Methods: In this prospective study, a total of 226 stool and 178 plasma samples were received from patients referred to colonoscopy units. tM2-PK enzyme was measured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples. Results: According to ROC curves, in the tumor group, at the cutoff value of 4 U/ml, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in the polyp group, the sensitivity and specificity were 87 and 68%, respectively. For tumor detection in plasma specimens, a cutoff value > 25 U/ml has a sensitivity and specificity of 90.9 and 91.3%, respectively. Similarly, for polyp detection, a cutoff value > 19 U/ml has a sensitivity of 96.3% and the specificity of 85.5%. Conclusions: Based on our results, a cutoff range of 4.8-8 U/ml and > 8 U/ml could be used to detect polyp and tumor in stool samples, respectively. Similarly, a cutoff range of 19-25 U/ml and > 25 U/ml is recommended in plasma samples, suggesting tM2-PK test as a non-invasive assay to diagnose CRC and adenomatous polyps.

show abstract

Section: Discussionmentioning

confidence: 94%

“…It does not have false positive results originating from various noncancerous sources of bleeding, such as hemorrhoids and fissures. In contrast to FOBT, only one small stool sample (from a single stool passage) is requested without dietary restrictions for the test [14].…”

Section: Introductionmentioning

confidence: 99%

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Also, in another study with 328 patients and the tumor M2-PK cut-off level of 4 U/mL, the sensitivity, speci city, PPV, and NPV were 71.4%, 71.0%, 73.5%, and 94.4%, respectively [20]. In a study by Hisham K. Dabbous et al, M2-PK was the most sensitive and speci c test in differentiating CRC from control subjects in fecal samples with sensitivity and speci city of 75%, and 100%, respectively [14].…”

Section: Discussionmentioning

confidence: 96%

“…Participants older than 30 years were categorized according to their age, sex, alcohol consumption, diabetes, smoking status and a family history of CRC. Patients with in ammatory bowel disease (Crohn and colitis disease) were not included in the study because recent reports indicate that the in ammatory bowel diseases can increase the M2-PK enzyme level [14][15][16].…”

Section: Sample Preparationmentioning

confidence: 99%

See 1 more Smart Citation

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

Rigi

Jannatabad

Izanloo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cancerous proliferating cells, has been used as a diagnostic biomarker for colorectal cancer (CRC). The aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population. Methods: In this prospective study, a total of 226 stool and 178 plasma samples were received from patients referred to colonoscopy units. tM2-PK enzyme was measured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples. Results: According to ROC curves, in the tumor group, at the cut-off value of 4 U/ml, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in the polyp group, the sensitivity and specificity were 87% and 68%, respectively. For tumor detection in plasma specimens, a cut-off value >25 U/ml has a sensitivity and specificity of 90.9% and 91.3%, respectively. Similarly, for polyp detection, a cut-off value >19 U/ml has a sensitivity of 96.3% and the specificity of 85.5%. Conclusions: Based on our results, a cut-off range of 4.8-8 U/ml and >8 U/ml could be used to detect polyp and tumor in stool samples, respectively. Similarly, a cut-off range of 19-25 U/ml and >25 U/ml is recommended in plasma samples, suggesting tM2-PK test as a non-invasive assay to diagnose CRC and adenomatous polyps.

show abstract

Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer

Vanarsa

Zhang

et al. 2021

J Gastroenterol

View full text Add to dashboard Cite

Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer

Cited by 18 publications

References 20 publications

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer

Contact Info

Product

Resources

About